Sign in

    Albert Bourla

    Chairman and CEO at Pfizer Inc
    Board
    Since January 2019
    Age
    63 years
    Education
    Holds a Doctor of Veterinary Medicine and a Ph.D. in Biotechnology of Reproduction.
    Tenure
    Joined Pfizer in 1993 and has held numerous leadership roles including President and General Manager of the Established Products Business Unit (2010-2013), Group President roles in February 2016 and June 2016, Chief Operating Officer from January 2018 to December 2018, before becoming Chief Executive Officer in January 2019 and Chairman in January 2020.

    Also at Pfizer Inc

    AM
    Aamir Malik
    Chief U.S. Commercial Officer and EVP
    AdG
    Alexandre de Germay
    Chief International Commercial Officer and EVP
    CB
    Chris Boshoff
    Chief Scientific Officer and President, R&D

    About

    Albert Bourla was born in 1962 and has developed a passion for science and innovation from an early age. He pursued a career in veterinary medicine and biotechnology, earning advanced degrees that have laid the foundation for his success. His educational background provided him with the skills required to contribute significantly to the field of biopharmaceuticals.

    Over the span of more than 25 years at Pfizer, he started his journey with the company in 1993 and steadily advanced through a variety of roles in key divisions. His career is highlighted by pivotal leadership positions, where he was responsible for strategic initiatives, product development, and driving global commercial operations. His contributions have been instrumental in the development of groundbreaking treatments, including playing a central role in the rapid development of the COVID-19 vaccine.

    Beyond his roles within the company, he has been actively involved in shaping Pfizer’s corporate culture and strategy. His leadership has not only focused on scientific innovation and operational excellence but has also emphasized corporate social responsibility, diversity, and global healthcare equity. These initiatives under his stewardship have reinforced Pfizer's reputation as a leader in the biopharmaceutical industry.

    $PFE Performance Under Albert Bourla

    Past Roles

    Organization Role Date Range Details
    Pfizer Chief Operating Officer January 2018 - December 2018 N/A
    Pfizer Group President, Pfizer Innovative Health June 2016 - December 2017 N/A
    Pfizer Group President, Global Innovative Pharma Business February 2016 - June 2016 Responsible for Vaccines, Oncology, and Consumer Healthcare since 2014
    Pfizer President and General Manager of Established Products Business Unit December 2010 - December 2013 N/A

    Fixed Compensation

    Data from  FY 2023
    Component NameAmount ($)Payment ScheduleAdditional Details
    Base Salary1,787,500 AnnualFixed base salary for 2023
    Aircraft Usage154,520 AnnualIncremental cost for personal use of company aircraft
    Financial Counseling15,000 AnnualAllowance for financial counseling, including tax preparation and estate planning
    Car Usage23,733 AnnualIncremental cost for personal use of a car and driver
    Security789,495 AnnualAdditional security protection due to heightened security risks
    Other2,443 AnnualIncidental items provided in connection with Pfizer business meetings
    Savings Plan Contributions16,500 AnnualEmployer contributions under the Savings Plan
    Supplemental Savings Plan Contributions1,257,563 AnnualEmployer contributions under the Supplemental Savings Plan

    Performance Compensation

    Data from  FY 2023

    Performance Share Awards (PSAs)

    Metric [Unit/Scale]**ValueDetails
    Grant DateFeb 23, 2023 Date the PSAs were granted
    Grant Date Fair Value$8,745,187 Determined using the closing stock price on the grant date
    Grant Date Stock Price$42.30 Stock price on the grant date
    Threshold Shares0 shares No payout if performance is below threshold
    Target Shares206,742 shares Target award based on performance goals
    Maximum Shares413,484 shares Cap on shares that can be earned if performance exceeds targets
    Payout Range0% to 200% Determined by achievement of adjusted net income and total shareholder return (TSR) over 2023–2025
    Vesting Schedule3 years (extendable to 5 years) PSAs vest on the third anniversary, with an option to extend vesting to the fifth anniversary if elected
    Performance Period2023–2025 Three-year period over which performance is measured

    Total Shareholder Return Units (TSRUs)

    Metric [Unit/Scale]**ValueDetails
    Grant DateFeb 23, 2023 Date the TSRUs were granted
    Grant Date Fair Value$8,761,683 TSRU award fair value on the grant date
    Grant Date Stock Price$42.30 Stock price on the grant date
    Vesting Schedule3 years TSRUs vest on the third anniversary and are settled on the fifth or seventh anniversary

    Non-Equity Incentive Plan Compensation

    Metric [Unit/Scale]**ValueDetails
    Threshold Payout$0 Minimum payout threshold
    Target Payout$3,575,342 Target bonus payout if financial goals are met
    Maximum Payout$8,938,355 Maximum possible payout under the plan
    Actual Payout$0 No payout was made as Pfizer did not achieve the required financial targets in 2023
    Performance PeriodJan 1, 2023 – Dec 31, 2023 Evaluation period for the non-equity incentive plan

    Short-Term Incentive Bonus

    Metric [Unit/Scale]**ValueDetails
    Actual Bonus Award$0 No short-term bonus awarded due to missed financial targets
    Performance Period2023 Financial performance period for short-term incentives

    This comprehensive breakdown explains the performance compensation components for 2023, including detailed metrics, targets, vesting schedules, and performance periods with exact dollar amounts and share units as available.